Can Granix (Filgrastim) Cause a WBC of 38.34 × 10⁹/L?
Yes, Granix (filgrastim) can absolutely cause a white blood cell count of 38.34 × 10⁹/L, and this represents an expected pharmacologic response to G-CSF therapy that requires dose adjustment or discontinuation but is not inherently dangerous in most clinical contexts.
Mechanism and Expected Response
Filgrastim is a granulocyte colony-stimulating factor that directly stimulates neutrophil proliferation, differentiation, and release from bone marrow, making leukocytosis an anticipated effect rather than a complication 1.
The drug's mechanism of action specifically targets neutrophil progenitor cells, leading to dose-dependent increases in circulating white blood cells, predominantly neutrophils 2.
Evidence of Leukocytosis with Filgrastim
In cancer patients receiving myelosuppressive chemotherapy, white blood cell counts of 100,000/mm³ or greater were observed in approximately 2% of patients receiving filgrastim at dosages above 5 mcg/kg/day 3.
A WBC of 38.34 × 10⁹/L (38,340/mm³) falls well within the range of expected filgrastim-induced leukocytosis and is substantially below the threshold for severe hyperleukocytosis 3.
Clinical studies demonstrate that filgrastim elevates WBC nadirs and accelerates recovery, with the magnitude of response being dose-dependent 4.
Management Algorithm
When to Discontinue or Hold Filgrastim
For patients receiving chemotherapy:
- Discontinue filgrastim if the ANC surpasses 10,000/mm³ after the chemotherapy-induced ANC nadir has occurred 3.
- A WBC of 38.34 × 10⁹/L clearly exceeds this threshold and warrants immediate discontinuation 3.
For PBPC mobilization:
- Discontinue filgrastim if the leukocyte count rises to >100,000/mm³ 3.
- At 38.34 × 10⁹/L, continue monitoring but discontinuation is not mandatory unless the count continues to rise 3.
Expected Time Course After Discontinuation
Discontinuation of filgrastim therapy usually results in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to pretreatment levels in 1 to 7 days 3.
This rapid reversibility confirms that the leukocytosis is a direct pharmacologic effect rather than a pathologic process 3.
Clinical Context Matters
Distinguish from Pathologic Leukocytosis
Filgrastim-induced leukocytosis occurs with rising total neutrophil counts and improving clinical status, in contrast to infectious left shift which presents with neutropenia, fever, and clinical deterioration 5.
The left shift typically appears as neutrophil recovery begins, usually 6-14 days after chemotherapy, and is an expected response to filgrastim therapy 5.
If left shift occurs with fever (≥38.0°C), obtain blood and urine cultures and initiate broad-spectrum antibiotics immediately, but absence of fever or clinical signs of infection supports benign etiology 5.
Monitor for Complications
Monitor complete blood counts at least twice weekly during filgrastim therapy to detect excessive leukocytosis early 3.
Dosages of filgrastim that increase the ANC beyond 10,000/mm³ may not result in any additional clinical benefit 3.
Rare but Serious Complications
Hyperleukocytosis Syndrome
Although rare, lipegfilgrastim (a long-acting G-CSF) has been reported to cause hyperleukocytosis with associated weakness, loss of appetite, elevated LDH, and uric acid levels 6.
In the reported case, appropriate hydration and allopurinol treatment prevented progression to tumor lysis syndrome 6.
At a WBC of 38.34 × 10⁹/L, monitor for symptoms of hyperleukocytosis (weakness, loss of appetite) and check LDH and uric acid levels if clinically indicated 6.
Other Considerations
Thrombocytopenia has been reported in patients receiving filgrastim products; monitor platelet counts 3.
Cutaneous vasculitis has been reported, particularly in patients with severe chronic neutropenia receiving long-term filgrastim therapy; hold therapy if this develops 3.
Common Pitfalls to Avoid
Do not continue filgrastim unnecessarily once the ANC has recovered above 10,000/mm³, as achieving higher counts provides no additional clinical benefit and increases risk of adverse effects 3.
Do not confuse filgrastim-induced leukocytosis with leukemia or infection; the clinical context (recent chemotherapy, improving status, absence of fever) and rapid reversibility after discontinuation distinguish this from pathologic processes 5.
Do not administer filgrastim simultaneously with chemotherapy or within 24 hours before or after chemotherapy, as this increases the risk of severe thrombocytopenia and worsens outcomes 3, 1.